Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Faron announces its unaudited interim results for the six months ended 30 June 2019.
OncoCyte, a global oncology diagnostics company, recently announced that it will acquire Razor Genomics, which has developed a novel molecular diagnostic test for early-stage non-small cell lung cancer.
Using a combination of machine learning and parallel chemistry to change the way we think about treating disease
The dermatological drug maker will use Chapter 11 protection to restructure the company, including a possible sale of assets, and will delay development of its Phase III-ready psoriasis treatment.
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens.
CMR Surgical Limited announces that it has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
Race Oncology Limited is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.
Khanu Management GmbH, a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG, based in Dortmund, Germany.
New facilities expand services offering to Irish and International customers
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.